A draft of the Trump administration’s highly anticipated blueprint on health policy takes a softer approach to regulating companies than many had feared, a relief for industry and setback for ...

Hims & Hers saw 73% revenue growth, driven by subscriber gains and ARPU hikes. Read here for an in-depth investment analysis ...

US stocks opened mixed Friday as strong retail sales data offset hotter wholesale inflation, with UnitedHealth surging on ...

The disclosure in a filing Thursday gave a much-needed boost to the beleaguered health insurance giant, which saw shares jump as much as 9.6% in post-market trading. In other news: Nike co-founder ...

Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what ...

Stock index futures rose on Friday, with Dow futures leading the charge, as UnitedHealth got a boost after Berkshire Hathaway ...

Telehealth and wellness platform Hims & Hers Health ($HIMS) recently disappointed investors with its mixed second-quarter ...

Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed the Federal Trade Commission has been investigating the telehealth ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

After Bloomberg reported, citing people familiar with the probe, that the Federal Trade Commission has been investigating ...

The FTC has been probing Hims & Hers Health’s business practices for more than a year, including whether it has made it too hard for customers to ...